GlaxoSmithKline shoots for combo attack against melanoma in surgery patients

Fierce Biotech
February 1, 2013

GlaxoSmithKline is running a placebo controlled study to examine the benefit to late stage melanoma patients of combined therapies. They are testing “BRAF blocker dabrafenib and MEK inhibitor trametinib in patients whose BRAF V600E mutation-positive melanoma has been surgically removed.”

Roche/Genentech is also testing combination therapy with “MEK inhibitor GDC-0973 from its partner Exelixis ($EXEL) and its approved BRAF inhibitor Zelboraf.”

Some patients on these drugs, dabrafenib and trametinib, have developed another skin cancer, cutaneous squamous cell carcinoma.

patients on the combo lived 9.4 months without their cancer worsening compared with 5.8 months in the dabrafenib-only group.

 

Advertisements

Leave a comment

Filed under Clinical Trials, Companies, Medications

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s